The Pneumococcal AMC

in page functions
 

Underlined label (for homepage use only) 

Title
(Keep concise to take into account avoidance of line wrap when this spans over 1 column only) 
The Pneumococcal AMC
Highlight contents: 

The pneumococcal Advance Market Commitment (AMC) is an innovative way to make effective and affordable pneumococcal vaccines available for children in developing countries.

The AMC provides incentives for manufacturers to produce large quantities of pneumococcal vaccine which can then reach developing countries as much as a decade earlier than they historically would have done. The AMC is funded by Canada, Italy, Norway, the Russian Federation, the United Kingdom and the Bill & Melinda Gates Foundation.

Read the 2012 Pneumococcal AMC Annual Report. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.


Image:  Feature image caption: 


Link(s): 
Link Item
Link:

39%

Over the course of a decade, the weighted average price of pentavalent vaccine dropped by 39% from US$ 3.56 in 2003 to US$ 2.17 per dose in 2012, with a lowest ever price of US$ 1.19 per dose from one supplier in 2013.

GAVI Alliance 2013

More facts...

close icon

modal window here